Nomura Asset Management Co. Ltd. Boosts Stake in Gilead Sciences, Inc. $GILD

Nomura Asset Management Co. Ltd. boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 842,183 shares of the biopharmaceutical company’s stock after buying an additional 4,598 shares during the period. Nomura Asset Management Co. Ltd. owned 0.07% of Gilead Sciences worth $103,370,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in GILD. Ares Financial Consulting LLC purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at $28,000. Financial Consulate Inc. lifted its holdings in shares of Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares during the last quarter. North Star Investment Management Corp. lifted its holdings in shares of Gilead Sciences by 54.8% during the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 86 shares during the last quarter. MTM Investment Management LLC lifted its holdings in shares of Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares during the last quarter. Finally, BOCHK Asset Management Ltd purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at $31,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Trading Down 1.3%

GILD stock opened at $134.43 on Friday. The company’s 50-day simple moving average is $135.30 and its 200-day simple moving average is $134.09. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 52-week low of $104.46 and a 52-week high of $157.29. The firm has a market cap of $166.90 billion, a P/E ratio of 18.31 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same period in the prior year, the company posted $1.81 EPS. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities analysts forecast that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the sale, the chief executive officer directly owned 632,567 shares of the company’s stock, valued at $81,702,353.72. This represents a 1.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the sale, the chief financial officer directly owned 173,191 shares in the company, valued at approximately $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 53,000 shares of company stock valued at $7,075,670 in the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on GILD shares. Wolfe Research increased their price objective on Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a report on Thursday, February 12th. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a report on Wednesday, May 20th. Sanford C. Bernstein reiterated an “outperform” rating and set a $160.00 price objective on shares of Gilead Sciences in a report on Wednesday, February 11th. Jefferies Financial Group started coverage on Gilead Sciences in a report on Tuesday, March 10th. They set a “buy” rating and a $180.00 price objective for the company. Finally, JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Twenty-five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $156.93.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.